Technology
Health
Pharmaceutical

CytRx

$0.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-1.75%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CytRx and other stocks, options, ETFs, and crypto commission-free!

About

CytRx Corporation Common Stock, also called CytRx, is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Read More The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Employees
6
Headquarters
Los Angeles, California
Founded
1985
Market Cap
18.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
155.66K
High Today
$0.61
Low Today
$0.5528
Open Price
$0.58
Volume
135.10K
52 Week High
$1.37
52 Week Low
$0.33

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Medical
Biopharmaceutical
Research And Development
US

News

Yahoo FinanceMay 15

CytRx: 1Q Earnings Snapshot

LOS ANGELES (AP) _ CytRx Corp. (CYTR) on Wednesday reported a loss of $1.4 million in its first quarter. The Los Angeles-based company said it had a loss of 4 cents per share. Losses, adjusted to account for discontinued operations, were 5 cents per share. The company's shares closed at 52 cents. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CYTR at h...

97
Yahoo FinanceMay 15

CytRx Corporation Reports First Quarter 2019 Financial Results

Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing Agreements LOS ANGELES, May 15, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the first quarter ended March 31, 2019, and provided an overview of recent accomplishments and plans for its r...

39
Yahoo FinanceMay 8

CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

The Patent Covers the Use of Aldoxorubicin Intravenously, Intra-Arterially or Intramuscularly for the Treatment of Brain Cancer LOS ANGELES, May 8, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of aldoxorubicin intravenously, intra-arterially or intramuscularly for the treatment of brain cancer, which patent was...

964

Earnings

-$0.19
-$0.14
-$0.10
-$0.05
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.06 per share
Actual
-$0.05 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.